Dutta Dilip Kumar, Dutta Indranil
J Indian Med Assoc. 2013 Aug;111(8):553-5.
To find out the safety, effectiveness and tolerability of using desogestrel (75 microg/day), a progesterone only pill on lactating mother, a prospective clinical study was undertaken among 200 lactating women during the period from 1st January 2010 to 13th June 2011 at Gice Clinic, Kalyani, Nadia, West Bengal. The same number of cases were taken as placebo for comparison. Desogestrel was started after six weeks of delivery for six months. Patients were reviewed at 8th, 12th, 16th, 24th weeks and one year. The very interesting results were found from the follow-up study that desogestrel (75 microg/day) did not alter the amount and composition of breast milk, pregnancy was not reported as compared to placebo. The drug had good tolerability, less side-effects and did not affect the growth and development of breastfed babies. Due to the safety, good efficacy, tolerability and less side-effects it is concluded that desogestrel (75 microg/day) was well accepted in majority of women (97.5%) and provided good contraceptive efficacy during the lactating period. This treatment does not have any effect on the growth and development of breastfed baby.
为了探究使用去氧孕烯(每日75微克)这种仅含孕激素的避孕药对哺乳期母亲的安全性、有效性和耐受性,2010年1月1日至2011年6月13日期间,在西孟加拉邦纳迪亚区卡利亚尼的吉斯诊所,对200名哺乳期妇女进行了一项前瞻性临床研究。选取相同数量的病例作为安慰剂对照。产后六周开始服用去氧孕烯,持续六个月。在第8周、12周、16周、24周和一年时对患者进行复查。随访研究得出了非常有趣的结果,即去氧孕烯(每日75微克)并未改变母乳的量和成分,与安慰剂组相比未报告有妊娠情况。该药物耐受性良好,副作用较少,且不影响母乳喂养婴儿的生长发育。鉴于其安全性、良好的疗效、耐受性和较少的副作用,得出结论:去氧孕烯(每日75微克)在大多数女性(97.5%)中被广泛接受,在哺乳期提供了良好的避孕效果。这种治疗方法对母乳喂养婴儿的生长发育没有任何影响。